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Abstract 
Objective: To compare pregnancy rates 
between lean, overweight, and obese women 
with polycystic ovary syndrome (PCOS) 
undergoing ovulation induction-intrauterine 
insemination (OI-IUI). 
Design: Retrospective cohort study 
Setting: Academic training program 
Patient(s):  All women with PCOS undergoing 
OI-IUI from January 2000 to November 2013. 
Interventions: Ovulation induction-intrauterine 
insemination with oral (oral OI-IUI) or combined 
oral and injectable (combined OI-IUI) agents. 
Main Outcome Measures: Clinical pregnancy 
rates (CPR) per IUI were compared in 198 
women undergoing oral OI-IUI and combined 
OI-IUI. Multivariate logistic regression was used 
to calculate the odds of clinical pregnancy while 
adjusting for potential confounders.  Results 
were expressed as adjusted odds ratios (OR) 
with 95% confidence intervals (CI), using lean 
women as the referent population.  
Results: In lean PCOS patients undergoing 
combined OI-IUI, the unadjusted CPR was 52%; 
CPR was comparatively lower in overweight 
(22%), obese (27%) and morbidly obese (21%) 
women for all cycles. Adjusting for age and 
duration of infertility, the odds of clinical 
pregnancy after combined OI-IUI was 
significantly diminished in overweight (OR=0.27 
CI=0.12-0.63), obese (OR=0.41, CI=0.20-0.83) 
and morbidly obese women (OR=0.33 CI=0.14-
0.78) as compared to the lean PCOS referent. A 
similar but non-significant trend was identified in 
women undergoing oral OI-IUI.  
Conclusion: Lean women with PCOS have a 
higher CPR after combined OI-IUI as compared 
to their overweight, obese, and morbidly obese 
counterparts. Patients with a lean PCOS 
phenotype may preferentially benefit from this 
treatment approach. 
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Introduction  
The prevalence of polycystic ovary 
syndrome (PCOS) in the general female 
population ranges from 5-10%,1,2 and 
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the disease accounts for nearly 73% of 
cases of anovulatory infertility.3,4 The 
disease process is characterized by 
variable degrees of hyperandrogenism, 
morphologic changes in the ovary, 
inappropriate gonadotropin secretion, 
and insulin resistance – all of which 
contribute to the phenotype of ovulatory 
dysfunction and infertility.5  
Obesity, defined by the World Health 
Organization (WHO) as a body mass 
index (BMI) of >30 kg/m2, is an 
increasing health concern in the United 
States.  Recent estimates identify 
greater than 31% of reproductive-aged 
American women as obese, and nearly 
55% as overweight (BMI >25 kg/m2).6 A 
majority of PCOS patients are 
overweight or obese,1 and obesity 
contributes to several metabolic 
alterations that interfere with normal 
ovulation through increased peripheral 
aromatization resulting in 
hyperestrogenemia, decreased sex-
hormone binding globulin (SHBG) 
resulting in increased free testosterone 
levels, and hyperinsulinemia resulting in 
higher thecal androgen production.4,7 
Despite its strong association with the 
disease, obesity is not requisite for the 
diagnosis of PCOS and approximately 
25-30% of women with PCOS are of 
normal BMI (18.5-25 kg/m2).  These 
women are thought to be at lower risk 
for the metabolic dysfunction typically 
associated with PCOS, indicating that 
obesity, rather than PCOS, may be the 
primary contributor to this risk.8  
There is little data describing fertility 
potential in the lean PCOS variant.  A 
few recent studies have compared in 
vitro fertilization (IVF) outcomes in the 
lean versus obese PCOS populations, 
with two groups reporting lower 
pregnancy rates in obese PCOS 
patients9,10 and a third reporting no 
difference.11 Even less is known about 
the impact of BMI on pregnancy 
outcome in PCOS patients undergoing 
ovulation induction (OI), despite this 
being considered the first line treatment 
for this population.  We sought to 
compare clinical pregnancy rates (CPR) 
between lean, overweight, and obese 
PCOS patients undergoing ovulation 
induction and intrauterine insemination 
(OI-IUI) with oral (oral OI-IUI) or 
combined oral and injectable 
medications (combined OI-IUI).   
Materials and Methods  
Study Population 
The study population included women 
aged 21-43 who underwent OI-IUI at the 
University of Iowa between January 
2000 and November 2013.  Analyses 
were restricted to women with the sole 
infertility diagnosis of PCOS as defined 
by the 2003 Rotterdam criteria.12 
Couples who had multiple infertility 
diagnoses (including endometriosis, 
tubal factor, or diminished ovarian 
reserve) were excluded, as were those 
with severe male factor, as defined by a 
pre-wash total motile sperm count of 
less than 10 million averaged over all 
semen analyses performed.  Pregnancy 
outcome data was lacking for three 
patients during the study period and 
these individuals were also excluded 
from analyses. The method of ovulation 
induction was selected by the individual 
provider, and consisted of either oral 
ovulation induction with clomiphene 
citrate or letrozole, or combined 
oral/injectable ovulation induction with 
clomiphene citrate or letrozole in 
conjunction with gonadotropins.  Oral 
ovulation induction cycles were typically 
monitored using home urinary luteinizing 
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hormone (LH) kits, whereas combined 
oral/injectable ovulation induction cycles 
were monitored with serial sonographic 
measurements of follicular growth 
beginning on treatment day 8.  
Spontaneous ovulation was permitted in 
oral ovulation induction cycles, whereas 
250 mcg of subcutaneous recombinant 
human chorionic gonadotropin (hCG) 
was used to trigger ovulation in 
combined oral/injectable ovulation 
induction cycles.  IUI was performed 36 
hours after hCG trigger or 24 hours after 
a positive home urinary LH kit.  The 
study was approved by the Institutional 
Review Board at The University of Iowa. 
Exposure and outcome variables 
Body mass index was calculated as 
weight in kilograms over height in 
meters squared based on 
measurements obtained at the initiation 
of treatment. Body mass index was 
categorized based on World Health 
Organization cut points as lean (<25 
kg/m2), overweight (25.0-29.9 kg/m2), 
obese (30.0-39.9 kg/m2), or morbidly 
obese (>40 kg/m2).  Lean women were 
used as the referent population for all 
comparisons.  The primary outcome 
was clinical pregnancy, defined as 
sonographic evidence of intrauterine 
gestational sac on ultrasound.  Clinical 
pregnancy rates were calculated per 
completed IUI.   
Potential confounding variables  
Female age, parity, and IUI attempt 
number were documented at cycle start.  
Other patient variables assessed at the 
time of IUI included current smoking 
status (yes/no), current metformin use 
(yes/no), semen parameters (average 
pre-wash total motile count averaged for 
all IUI cycles), and duration of infertility 
(months). Documented cycle 
characteristics included type of OI 
(letrozole, clomiphene citrate, +/- 
gonadotropins), utilization of an hCG 
trigger (yes/no), and for combined OI-IUI 
cycles, total number of follicles and 
number of follicles > 15mm on day of 
hCG trigger.  
Statistical Analysis 
Logistic regression was used to 
estimate the effect of BMI on clinical 
pregnancy, adjusting for potential 
confounders including parity, cycle 
number, smoking status, metformin use, 
semen parameters, type of oral agent 
used, utilization of hCG trigger, and total 
number of follicles and number of 
follicles > 15mm on day of hCG trigger 
for combined OI-IUI cycles.  Female age 
and duration of infertility were included a 
priori as covariates in the model.  Other 
potential confounders were examined 
but resulted in a less than 10% change 
in the effect estimates and were 
therefore not included in the final model.  
Generalized estimating equations were 
used to account for the correlation 
between multiple cycles in the same 
patient.  Results were expressed as 
adjusted odds ratios (OR) with 95% 
confidence intervals (CI), using lean 
women as the referent population.  
Results  
One hundred ninety eight women with 
PCOS contributed a total of 440 cycles 
to the analysis: 114 cycles from 48 lean 
women, 87 cycles from 38 overweight 
women, 146 cycles from 65 obese 
women, and 93 cycles from 47 morbidly 
obese women. Demographic 
characteristics of the study population 
are listed in Table 1.  Fifty-seven 
percent of participants were obese or 
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morbidly obese. Patient age and 
duration of infertility both rose with 
increasing BMI, whereas smoking 
status, parity, and average total motile 
sperm counts were similarly distributed 
across all BMI categories. Use of 
metformin was more common among 
obese women.  There was more 
clomiphene use in the oral OI-IUI cycles 
(66% of all cycles), and more letrozole 
use (75% of all cycles) in the combined 
OI-IUI cycles. The total number of 
follicles measured on ultrasound at time 
of hCG trigger in combined OI-IUI cycles 
was higher for lean patients than 
overweight or obese patients, though 
the median number of follicles >15mm 
at time of hCG injection did not 
substantially differ between BMI 
categories. 
Table 1. Characteristics of 198 women and 440 ovulation induction and 
intrauterine insemination cycles among women with polycystic ovary syndrome 
 Lean 
(BMI <25) 
Overweight 
(BMI 25-29.9) 
Obese 
(BMI 30-39.9) 
Morbidly obese 
(BMI <40.0) 
Patient characteristics N=48 N=38 N=65 N=47 
Age at insemination (years)a 29.2 (3.8) 28.7(4.1) 30.4 (4.3) 31.1 (4.6) 
Parityb 
0 
1 
2 
 
42 (89%) 
3 (6%) 
2 (4%) 
 
30 (81%) 
6 (16%) 
1 (3%) 
 
54 (83%) 
9 (14%) 
2 (3%) 
 
39 (83%) 
7 (15%) 
1 (2%) 
Current smokerb 4 (9%) 2 (7%) 11 (20%) 6 (18%) 
Duration of infertility (months)c 18 (12-24) 24 (18-33) 27 (18-48) 36 (18-60) 
Cycle characteristics N=114 N=87 N=146 N=93 
Oral OI agentb 
    Clomiphene 
    Letrozole    
 
50 (74%) 
18 (26%) 
 
18 (44%) 
23 (56%) 
 
41 (80%) 
10 (20%) 
 
20 (57%) 
15 (43%) 
Combined OI agentsb 
    Clomiphene 
    Letrozole 
 
9 (20%) 
37 (80%) 
 
15 (33%) 
31 (67%) 
 
26 (27%) 
69 (73%) 
 
11 (19%) 
47 (81%) 
hCG triggerb 59 (52%) 51 (59%) 102 (70%) 66 (72%) 
Metforminb 13(11%) 15 (17%) 50 (34%) 27 (29%) 
Average total motile sperm count (x106)c 64.5 (33-128) 57 (33-153) 71.5 (40-134) 57 (30-100) 
Combined OI-IUI cycles only N=46 N=44 N=90 N=52 
Total folliclesc    6 (4-28) 4 (3-6) 4 (2-16) 3 (2-6) 
Follicles >15mmc 1 (1-3) 2 (1-2) 1 (1-2) 1 (1-2) Note: BMI=body mass index; OI=ovulation induction; hCG= human chorionic gonadotropin; IUI= intrauterine insemination aResults expressed as mean (SD) bResults expressed as n (%) cResults expressed as median (interquartile range) 
 
Unadjusted rates of clinical pregnancy 
after the first cycle of oral OI-IUI showed 
no consistent association with patient 
BMI, but trended downward when all 
cycles were examined (Table 2).  
Adjusted analyses did not reveal a 
significant difference in odds of clinical 
pregnancy in overweight and obese 
women as compared to the lean PCOS 
referent population (Figure 1).   
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Table 2. Unadjusted rates of clinical pregnancy in 440 ovulation induction and 
intrauterine insemination cycles among women with polycystic ovary syndrome 
 Lean 
(BMI <25) 
Overweight 
(BMI 25-29.9) 
Obese 
(BMI 30-39.9) 
Morbidly obese 
(BMI <40.0) 
ORAL OI-IUI N=27/68 N=19/41 N=22/51 N=18/35 
Clinical pregnancy ratea 
    1st cycle 
    All cycles 
 
4 (15%) 
14 (21%) 
 
4 (21%) 
6 (15%) 
 
2 (9%) 
8 (16%) 
 
3 (17%) 
4 (11%) 
COMBINED OI-IUI N=21/46 N=19/46 N=43/95 N=29/58 
Clinical pregnancy ratea 
    1st cycle 
    All cycles 
 
13 (62%) 
24(52%) 
 
1 (5%) 
10 (22%) 
 
15 (35%) 
26 (27%) 
 
5 (17%) 
12 (21%) Note: BMI=body mass index; OI=ovulation induction; IUI=intrauterine insemination; N= number of first intrauterine insemination cycles / total number of intrauterine insemination cycles aResults expressed as n (%) 
 
In lean PCOS patients undergoing 
combined OI-IUI, the unadjusted CPR 
for all cycles was 52%; CPR was 
comparatively lower in overweight 
(22%), obese (27%) and morbidly obese 
(21%) women (Table 2).  Adjusting for 
age and duration of infertility, the odds 
of clinical pregnancy was significantly 
diminished in overweight, obese, and 
morbidly obese women with PCOS 
undergoing combined OI-IUI as 
compared to the lean referent (Figure 2)
 
Figure 1. Adjusted odds of clinical pregnancy after oral ovulation induction and 
intrauterine insemination in women with polycystic ovary syndrome
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Figure 2. Adjusted odds of clinical pregnancy after combined oral and injectable 
ovulation induction and intrauterine insemination in women with polycystic ovary 
syndrome 
 
Discussion 
The results of this study demonstrate a 
significant negative association between 
increasing patient BMI and rates of 
clinical pregnancy in women with PCOS 
undergoing combined ovulation 
induction and intrauterine insemination 
with oral and injectable medications. 
Although a similar association was not 
identified in women with PCOS 
undergoing ovulation induction and 
intrauterine insemination with oral 
agents, analyses were limited by the 
small number of total pregnancies in this 
population and the possibility of a 
difference cannot therefore be excluded.  
Retrospective studies have evaluated 
the effects of BMI on IVF cycle 
outcomes in women with PCOS,9-11 with 
discrepant results.  A recent study 
demonstrated a 66% lower odds of 
clinical pregnancy in obese (BMI>30 
kg/m2) as compared to lean (BMI<25 
kg/m2) women with PCOS after 
adjusting for female age, gravidity, day 3 
follicle stimulating hormone (FSH), and 
male factor infertility.10 A similar 
increase in clinical pregnancy rates in 
lean women with PCOS as compared to 
those with BMI>25 kg/m2 was identified 
by a second study that also 
demonstrated a preferential benefit of 
GnRH-agonist stimulation protocols in 
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the lean cohort.9 A third study 
comparing lean and obese women 
without PCOS to lean and obese 
women with PCOS demonstrated a 
greater number of retrieved oocytes in 
lean as compared to obese women with 
PCOS, but noted comparable rates of 
clinical pregnancy and live birth in all 
groups.  The results of this study were 
significantly limited by its small sample 
size which included only six lean 
patients with PCOS.11 These studies 
suggest that lean PCOS patients may 
have a differential response to ovarian 
stimulation in the setting of IVF, but 
could not comment on the association 
with more conservative types of infertility 
treatment. 
Our data appear consistent with the few 
existing studies examining the 
association between patient BMI and 
outcome of ovulation induction in 
women with PCOS.   The multi-center, 
randomized control trial comparing 
clomiphene and metformin for ovulation 
induction in women with PCOS by Legro 
and colleagues demonstrated 
significantly higher live birth rates in 
subjects with BMI <30 kg/m2.5  A post-
hoc analysis of the data demonstrated a 
negative association between increasing 
patient BMI and rates of clinical 
pregnancy similar to that identified in our 
study.  After ovulation induction with 
clomiphene, CPR ranged from 36.8% in 
women with BMI <30 kg/m2 to 19.0% in 
women with BMI 30-34 kg/m2 and 
19.1% in women with BMI > 35 kg/m2.   
A single retrospective study of 270 
women directly investigated the impact 
of obesity on cycle outcome in women 
with PCOS undergoing ovulation 
induction.  Treatment was initiated with 
clomiphene, and if no ovulation was 
documented in three cycles despite 
dose escalation, extended to 
gonadotropins.  Women who ovulated 
successfully with clomiphene were given 
up to six cycles to conceive before 
gonadotropin therapy.  The authors 
identified lower rates of ovulation and 
clinical pregnancy with increasing BMI, 
but data were unadjusted and did not 
account for key confounding factors 
including patient age.4 The study 
demographics also indicated a mean 
BMI of 28.5 +/- 5.5 kg/m2, which may 
limit the generalizability of its results to 
populations with a higher prevalence of 
obesity.   
Some key limitations should be 
considered when interpreting our 
results.  The study population was 
identified retrospectively from our 
institution’s database of couples 
undergoing IUI.  Pregnancy rates could 
accordingly only be determined per IUI, 
not per cycle start.  Cycles that were 
cancelled prior to IUI were therefore not 
included in the database, which may 
falsely elevate the overall rates of 
clinical pregnancy.  This may have 
particular relevance in lean women with 
PCOS undergoing combined OI-IUI, a 
population with a significant risk of cycle 
cancellation due to multi-follicular 
development, where our unadjusted 
pregnancy rates were as high as 50-
60%.  A false elevation in CPR among 
lean women could overestimate the 
potential negative impact of obesity on 
odds of clinical pregnancy in the PCOS 
population, thus skewing our results 
away from the null hypothesis.  This is 
supported by the absence of an 
association in the oral ovulation 
induction group where cycle cancellation 
rates are likely to be low.  It can be 
argued, however, that morbidly obese 
women may also have a high risk of 
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cycle cancellation due to provider desire 
to avoid multiple gestation pregnancies 
due to the significant obstetric 
consequences in this population. If this 
risk outweighs that of lean women, this 
may underestimate the impact of obesity 
on cycle outcome and skew data 
towards the null.  It is worth noting, 
however, that adjusting for the total 
number of follicles and number of 
follicles >15mm on the day of hCG 
trigger did not substantially change the 
effect estimates, suggesting that the 
negative impact of obesity on odds of 
clinical pregnancy may be independent 
of differences in ovarian response to OI.  
Additional limitations include the non-
standardized selection of patients for 
either oral or combined OI-IUI as well as 
the lack of statistical power to examine 
other outcomes of interest such as 
miscarriage or multiple pregnancy.   
Despite these limitations, this study is 
unique in its ability to examine the 
association between a wide range of 
patient BMI and outcome of ovulation 
induction in a well-defined cohort of 
PCOS patients.  The large number of 
total IUI cycles afforded us the ability to 
account for variables including age and 
duration of infertility that may confound 
the relationship between BMI and cycle 
outcome, particularly in the combined 
OI-IUI cycles.  Future prospective 
validation of these findings would afford 
the ability to examine differences in the 
medication dose required to achieve 
ovulation and account for the impact of 
cycle cancellation. 
Given the limited existing literature on 
response to ovulation induction in these 
populations, this study provides useful 
data for patient counseling with respect 
to infertility treatment selection.  The 
results of this study suggest that lean 
women with PCOS have higher 
pregnancy rates after combined OI-IUI 
with oral and injectable agents as 
compared to their overweight, obese, 
and morbidly obese counterparts, and 
may preferentially benefit from this 
treatment approach.   
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